Quick Answer
Xeris Biopharma Holdings, Inc. reported Total Assets of $383.53 million for the year ending 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +18.7% in Total Assets from 2024 to 2025.
- This data is from Xeris Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $131.26 million | Q1 2022: $337.62 million | Q2 2022: $318.62 million | Q3 2022: $303.02 million | Q1 2023: $321.36 million | Q2 2023: $328.78 million | Q3 2023: $327.78 million | Q1 2024: $336.62 million | Q2 2024: $331.73 million | Q3 2024: $321.10 million | Q1 2025: $315.45 million | Q2 2025: $334.69 million | Q3 2025: $370.19 million.
- Over the full 6 years of available data (2020 to 2025), Xeris Biopharma Holdings, Inc.'s Total Assets has grown by 141.0%.
- Historical annual values: Fiscal year 2025: $383.53 million | Fiscal year 2024: $323.06 million | Fiscal year 2023: $322.60 million | Fiscal year 2022: $344.52 million | Fiscal year 2021: $304.36 million | Fiscal year 2020: $159.15 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: